Itraconazole, a commonly used antifungal, inhibits Fcγ receptor-mediated phagocytosis: Alteration of Fcγ receptor glycosylation and gene expression

Shock

Volumn 42, Issue 1, 2014, Pages 52-59

  Niño, Diego F ^a,b   Cauvi, David M ^b   De Maio, Antonio ^b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California San Diego   (United States)

Author keywords

bacteria; cancer; Fc receptors; innate immunity; Macrophages; phagocytosis

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; ANTIFUNGAL AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL SURFACE; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; INCUBATION TIME; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MEMBRANE; DOSE RESPONSE; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; IMMUNOLOGY; INBRED MOUSE STRAIN; MACROPHAGE; METABOLISM;

ANIMALS; ANTIFUNGAL AGENTS; CELL MEMBRANE; CELLS, CULTURED; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GLYCOSYLATION; ITRACONAZOLE; MACROPHAGES; MALE; MICE, INBRED STRAINS; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 84902544548     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000169     Document Type: Article

References (37)

1. De Beule K, Van Gestel J: Pharmacology of itraconazole. Drugs 61(Suppl 1): 27-37, 2001.
2. Meis JF, Verweij PE: Current management of fungal infections. Drugs 61(Suppl 1):13-25, 2001.
3. Zonios DI, Bennett JE: Update on azole antifungals. Semin Respir Crit Care Med 29(2):198-210, 2008.
4. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, Liu JO: Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2(4):263-270, 2007.
5. Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO: The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem 286(51):44045-44056, 2011.
6. Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO: Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thoracic Oncol 8(5):619-623, 2013.
7. Frey T, De Maio A: The antifungal agent itraconazole induces the accumulation of high mannose glycoproteins in macrophages. J Biol Chem 284(25): 16882-16890, 2009.
8. Fukushima K, Takasaki S: Processing inhibition of N-linked sugar chains associated with induction of Fc receptorYmediated phagocytosis in the mouse monocytoid cells. Glycobiology 3(1):15-22, 1993.
9. Bilyy RO, Shkandina T, Tomin A, Munoz LE, Franz S, Antonyuk V, Kit YY, Zirngibl M, Furnrohr BG, Janko C, et al.: Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J Biol Chem 287(1): 496-503, 2012.
10. Nimmerjahn F, Ravetch JV: FcgammaRs in health and disease. Curr Top Microbiol Immunol 350:105-125, 2011.
11. Vega VL, De Cabo R, De Maio A: Age and caloric restriction diets are confounding factors that modify the response to lipopolysaccharide by peritoneal macrophages in C57BL/6 mice. Shock 22(3):248-253, 2004.
12. Loike JD, Shabtai DY, Neuhut R, Malitzky S, Lu E, Husemann J, Goldberg IJ, Silverstein SC: Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 24(11):2051-2056, 2004.
13. Flannagan RS, Jaumouille V, Grinstein S: The cell biology of phagocytosis. Annu Rev Pathol 7:61-98, 2012.
14. Chimaolera M, Launay P, Montenegro V, Rivero MC, Velasco IT, Monteiro RC: Enhanced expression of Fc alpha receptor I on blood phagocytes of patients with gram-negative bacteremia is associated with tyrosine phosphorylation of the FcR-gamma subunit. Shock 16:344-348, 2001.
15. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443-446, 2000.
16. Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327, 2010.
17. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH: Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol 186(5):2699-2704, 2011.
18. Bovolenta C, Gasperini S, Cassatella MA: Granulocyte colony-stimulating factor induces the binding of STAT1 and STAT3 to the IFNgamma response region within the promoter of the Fc(gamma)RI/CD64 gene in human neutrophils. FEBS Lett 386(2-3):239-242, 1996.
19. Flores-Borja F, Santiago E, Weiss-Steider B: [Fc gamma receptors in health and disease]. Rev Invest Clin 50(6):529-540, 1998.
20. Capsoni F, Minonzio F, Ongari AM, Carbonelli V, Galli A, Zanussi C: IL-10 up-regulates human monocyte phagocytosis in the presence of IL-4 and IFNgamma. J Leukoc Biol 58(3):351-358, 1995.
21. Ruhl S, Pluznik DH: Dissociation of early and late markers of murine myeloid differentiation by interferon-gamma and interleukin-6. J Cell Physiol 155(1): 130-138, 1993.
22. Santiago E, Mendoza JF, Corona TM, Lopez R, Sanchez L, Mora LM, Flores F, Valencia E, Weiss-Steider B: Induction of Fc receptors on murine macrophages and leukemic cells by interleukin-1 beta. Eur Cytokine Netw 4(3):223-228, 1993.
23. Kerst JM, van de Winkel JG, Evans AH, de Haas M, Slaper-Cortenbach IC, de Wit TP, von dem Borne AE, van der Schoot CE, van Oers RH: Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)Ypositive neutrophils via an effect on myeloid precursor cells. Blood 81(6):1457-1464, 1993.
24. Comber PG, Lentz V, Schreiber AD: Modulation of the transcriptional rate of Fc gamma receptor mRNA in human mononuclear phagocytes. Cell Immunol 145(2):324-338, 1992.
25. Comber PG, Rossman MD, Rappaport EF, Chien P, Hogarth PM, Schreiber AD: Modulation of human mononuclear phagocyte Fc gamma RII mRNA and protein. Cell Immunol 124(2):292-307, 1989.
26. Aittomaki S, Yang J, Scott EW, Simon MC, Silvennoinen O: Molecular basis of Stat1 and PU.1 cooperation in cytokine-induced Fcgamma receptor I promoter activation. Int Immunol 16(2):265-274, 2004.
27. Bigler RD, Brown HM, Guyre PM, Lund-Katz S, Scerbo L, Esfahani M: Effect of low-density lipoprotein on the expression of high-affinity Fc gamma receptors. Biochim Biophys Acta 1011(2-3):102-109, 1989.
28. Bigler RD, Khoo M, Lund-Katz S, Scerbo L, Esfahani M: Identification of low density lipoprotein as a regulator of Fc receptorYmediated phagocytosis. Proc Natl Acad Sci U S A 87(13):4981-4985, 1990.
29. Xu J, Dang Y, Ren YR, Liu JO: Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 107(10):4764-4769, 2010.
30. Liscum L: Niemann-Pick type C mutations cause lipid traffic jam. Traffic 1(3):218-225, 2000.
31. Chang TY, Reid PC, Sugii S, Ohgami N, Cruz JC, Chang CC: Niemann-Pick type C disease and intracellular cholesterol trafficking. J Biol Chem 280(22): 20917-20920, 2005.
32. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, et al.: Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277(5323):228-231, 1997.
33. Gelsthorpe ME, Baumann N, Millard E, Gale SE, Langmade SJ, Schaffer JE, Ory DS: Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding. J Biol Chem 283(13):8229-8236, 2008.
34. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM: Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 71(21):6764-6772, 2011.
35. Kim J, Tang JY, Gong R, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, et al.: Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17(4):388-399, 2010.
36. Ringshausen I, Feuerstacke Y, Krainz P, den Hollander J, Hermann K, Buck A, Peschel C, Meyer Zum Bueschenfelde C: Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts. Cancer Res 70(11):4292-4296, 2010.
37. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, Simpson JL, McElduff P, Gibson PG: Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 111(5):952-957, 2003.